Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
Boehringer Ingelheim
Moodys
AstraZeneca

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Omecamtiv Mecarbil

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Omecamtiv Mecarbil?

Omecamtiv Mecarbil is an investigational drug.

There have been 8 clinical trials for Omecamtiv Mecarbil. The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2018.

The most common disease conditions in clinical trials are Heart Failure, Ventricular Dysfunction, Left, and [disabled in preview]. The leading clinical trial sponsors are Amgen, Cytokinetics, and Servier.

There are fifteen US patents protecting this investigational drug and one hundred and ten international patents.

Recent Clinical Trials for Omecamtiv Mecarbil
TitleSponsorPhase
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureCytokineticsPhase 3
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureServierPhase 3
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureAmgenPhase 3

See all Omecamtiv Mecarbil clinical trials

Clinical Trial Summary for Omecamtiv Mecarbil

Top disease conditions for Omecamtiv Mecarbil
Top clinical trial sponsors for Omecamtiv Mecarbil

See all Omecamtiv Mecarbil clinical trials

US Patents for Omecamtiv Mecarbil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Omecamtiv Mecarbil   Start Trial Compounds, compositions and methods Cytokinetics, Incorporated (South San Francisco, CA)   Start Trial
Omecamtiv Mecarbil   Start Trial Compounds, compositions and methods Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
Omecamtiv Mecarbil   Start Trial Compounds, compositions and methods Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
Omecamtiv Mecarbil   Start Trial Disubstituted ureas and uses thereof in treating heart failure Amgen, Inc. (Thousand Oaks, CA)   Start Trial
Omecamtiv Mecarbil   Start Trial Ureas and their use in the treatment of heart failure Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
Omecamtiv Mecarbil   Start Trial Certain Chemical entities, compositions and methods Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Omecamtiv Mecarbil

Drugname Country Document Number Estimated Expiration Related US Patent
Omecamtiv Mecarbil Argentina 053405 2024-06-17   Start Trial
Omecamtiv Mecarbil Australia 2005264988 2024-06-17   Start Trial
Omecamtiv Mecarbil Brazil PI0512193 2024-06-17   Start Trial
Omecamtiv Mecarbil Canada 2570999 2024-06-17   Start Trial
Omecamtiv Mecarbil China 101035525 2024-06-17   Start Trial
Omecamtiv Mecarbil Cyprus 1115716 2024-06-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Harvard Business School
Boehringer Ingelheim
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.